28th May 2015 09:47
LONDON (Alliance News) - Motif Bio PLC said Thursday that it has received meeting minutes from the US Food and Drug Administration confirming the FDA's agreement with its phase III clinical development programme for its lead antibiotic product iclaprim.
The meeting with the FDA was held April 14.
Iclaprim is intended to tackle multi-drug resistant bacteria.
"This FDA confirmation supports Motif moving forward to begin the iclaprim Phase III clinical programme. The trials will investigate the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia, two serious and life threatening infections caused by multi-drug resistant bacteria," said Chief Executive Graham Lumsden in a statement.
Shares in Motif Bio are trading up 5.6% at 34.84 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
MTFB.L